The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday. About two weeks ago, the FDA sent Moderna a letter in which it refused to accept the application to review its first mRNA seasonal flu vaccine — a rare move by the federal agency that raised concern about another setback for the technology that’s been a target of some Trump administration health officials. The FDA told Moderna that its applicatio...